Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Levosimendan (Primary)
- Indications Pulmonary hypertension
- Focus Proof of concept; Therapeutic Use
- Sponsors Tenax Therapeutics
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 08 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 04 Apr 2018 According to a Tenax Therapeutics media release, the company will finalize trial protocol for IND submission and continue preparations to start of the trial by late June or July.